Adebrelimab (SHR-1316)

Clinical trials for Adebrelimab (SHR-1316) explained in plain language.

Never miss a new study

Get alerted when new Adebrelimab (SHR-1316) trials appear

Sign up with your email to follow new studies for Adebrelimab (SHR-1316), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New cocktail aims to shrink untreatable liver tumors

Disease control Not yet recruiting

This phase 2 trial tests a combination of low-dose bevacizumab (a blood vessel growth blocker) and adebrelimab (an immunotherapy) along with two liver-directed procedures (TACE and HAIC) as a first treatment for people with unresectable hepatocellular carcinoma, a type of liver c…

Matched conditions: ADEBRELIMAB (SHR-1316)

Phase 2 • Sponsor: Third Affiliated Hospital, Sun Yat-Sen University • Aim: Disease control

Last updated Jun 27, 2026 12:25 UTC

Adebrelimab (SHR-1316)

Get alerted when new Adebrelimab (SHR-1316) trials appear

New cocktail aims to shrink untreatable liver tumors